<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05620329</url>
  </required_header>
  <id_info>
    <org_study_id>LCCC1754</org_study_id>
    <nct_id>NCT05620329</nct_id>
  </id_info>
  <brief_title>UNC Pleural Fluid Registry</brief_title>
  <official_title>University of North Carolina Pleural Fluid Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNC Lineberger Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNC Lineberger Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Research with biospecimens such as blood, tissue, or body fluids can help researchers&#xD;
      understand how the human body works. Researchers can make new tests to find diseases,&#xD;
      understand how treatments work, or find new ways to treat a disease. The purpose of this&#xD;
      study is to collect biospecimens for research from patients with known or suspected lung&#xD;
      cancer. The information learned from the biospecimens may be used in future treatments. The&#xD;
      purpose of this protocol is to create a pleural fluid registry for use in future studies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 24, 2018</start_date>
  <completion_date type="Anticipated">January 24, 2050</completion_date>
  <primary_completion_date type="Anticipated">January 24, 2050</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>32 Years</target_duration>
  <primary_outcome>
    <measure>Creation of a pleural fluid registry</measure>
    <time_frame>32 years</time_frame>
    <description>Biological specimens and corresponding clinical data from subjects will be collected during standard of care procedures and medical record abstraction to support the creation of a pleural fluid registry.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">9999</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Lung Infection</condition>
  <condition>Breast Cancer</condition>
  <condition>Malignant Pleural Effusion</condition>
  <condition>Empyema</condition>
  <arm_group>
    <arm_group_label>Pleural Fluid Registry</arm_group_label>
    <description>Any subject who has pleural fluid buildup from lung cancer, breast cancer, or lung infection</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and pleural fluid&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        UNC patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who are 18 years or older&#xD;
&#xD;
          -  Inpatients and outpatients&#xD;
&#xD;
          -  Diagnosed with pleural fluid, are referred for and undergo clinically indicated&#xD;
             drainage who have clinical evidence of:&#xD;
&#xD;
          -  pulmonary infection (such as fever, leukocytosis, new or worsening infiltrate on chest&#xD;
             x-ray, or clinical deterioration) with effusion&#xD;
&#xD;
          -  malignancy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A subject will not be eligible for inclusion in this registry if, in the&#xD;
             investigator's (or treating clinician's) opinion, the patient has any concurrent&#xD;
             medical condition that may preclude their ability to undergo pleural fluid drainage&#xD;
             safely.&#xD;
&#xD;
          -  Incarcerated individuals&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Akulian</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNC Lineberger Comprehensive Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carmmen Garcia</last_name>
    <phone>+1 954-336-7499</phone>
    <email>carmmene@med.unc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Luz Cuaboy</last_name>
    <phone>+1 954-336-7499</phone>
    <email>luz_cuaboy@med.unc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UNC Lingeberger Comprehensive Cancer Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmmen Garcia</last_name>
      <phone>919-966-4432</phone>
      <email>carmmene@med.unc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Luz Cuaboy</last_name>
      <email>luz_cuaboy@med.unc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jason Akulian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://unclineberger.org/patientcare/clinical-trials/clinical-trials</url>
    <description>University of North Carolina Lineberger Comprehensive Cancer Center Clinical Trials</description>
  </link>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 9, 2022</study_first_submitted>
  <study_first_submitted_qc>November 9, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2022</study_first_posted>
  <last_update_submitted>November 9, 2022</last_update_submitted>
  <last_update_submitted_qc>November 9, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>biospecimen</keyword>
  <keyword>pleural fluid</keyword>
  <keyword>lung cancer</keyword>
  <keyword>cancer</keyword>
  <keyword>infection</keyword>
  <keyword>breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empyema</mesh_term>
    <mesh_term>Pleural Effusion, Malignant</mesh_term>
    <mesh_term>Pleural Effusion</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to share IPD with other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

